See more : nib holdings limited (NHF.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Taiwan Advance Bio-Pharmaceutical Inc. (4186.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Taiwan Advance Bio-Pharmaceutical Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Motorola Solutions, Inc. (0K3H.L) Income Statement Analysis – Financial Results
- First Republic Bank (FRC-PN) Income Statement Analysis – Financial Results
- Airesis SA (0QQV.L) Income Statement Analysis – Financial Results
- Velodyne Lidar, Inc. (VLDR) Income Statement Analysis – Financial Results
- Munjal Showa Limited (MUNJALSHOW.BO) Income Statement Analysis – Financial Results
Taiwan Advance Bio-Pharmaceutical Inc. (4186.TWO)
About Taiwan Advance Bio-Pharmaceutical Inc.
Taiwan Advance Bio-Pharmaceutical Inc. operates in the biotechnology industry in China Germany, USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, India, Pakistan, and internationally. The company provides food safety diagnostic testing kits; ELISA, rapid, and chemical test kits customization, and food safety lab establishment consultation services; and manufactures monoclonal and polyclonal antibody products. It also offers abused drugs rapid tests; provides cell banking services for newborn and adult stem cells storage; and operates drug testing center for urine drug test, hair drug test, and identification of drug abuse. The company was founded in 1989 and is based in New Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 315.98M | 318.24M | 243.36M | 235.57M | 205.80M |
| Cost of Revenue | 117.53M | 125.66M | 118.57M | 108.03M | 94.24M |
| Gross Profit | 198.46M | 192.58M | 124.79M | 127.55M | 111.56M |
| Gross Profit Ratio | 62.81% | 60.51% | 51.28% | 54.14% | 54.21% |
| Research & Development | 16.72M | 16.14M | 45.51M | 39.34M | 67.30M |
| General & Administrative | 45.41M | 50.01M | 48.49M | 57.87M | 65.09M |
| Selling & Marketing | 132.06M | 118.03M | 133.59M | 114.81M | 134.14M |
| SG&A | 177.47M | 168.04M | 182.08M | 172.67M | 199.24M |
| Other Expenses | 4.27M | 1.71M | -4.25M | 18.12M | 0.00 |
| Operating Expenses | 198.46M | 184.18M | 227.59M | 212.01M | 274.85M |
| Cost & Expenses | 315.98M | 309.84M | 346.16M | 320.03M | 369.09M |
| Interest Income | 1.49M | 495.00K | 124.00K | 137.00K | 224.00K |
| Interest Expense | 7.30M | 6.13M | 7.43M | 10.44M | 10.11M |
| Depreciation & Amortization | 25.90M | 28.18M | 30.39M | 33.72M | 24.98M |
| EBITDA | 21.81M | 38.79M | -76.69M | -39.18M | -128.36M |
| EBITDA Ratio | 6.90% | 12.19% | -31.44% | -13.79% | -63.16% |
| Operating Income | 4.27M | 10.61M | -106.92M | -66.21M | -154.97M |
| Operating Income Ratio | 1.35% | 3.33% | -43.93% | -28.10% | -75.30% |
| Total Other Income/Expenses | -15.66M | -4.72M | -7.53M | -16.92M | -18.20M |
| Income Before Tax | -11.39M | 3.69M | -114.44M | -83.13M | -173.17M |
| Income Before Tax Ratio | -3.60% | 1.16% | -47.03% | -35.29% | -84.15% |
| Income Tax Expense | -705.00K | 515.00K | 4.08M | 3.26M | 1.49M |
| Net Income | -10.68M | 3.17M | -118.53M | -86.39M | -174.67M |
| Net Income Ratio | -3.38% | 1.00% | -48.70% | -36.67% | -84.87% |
| EPS | -0.12 | 0.04 | -1.32 | -1.07 | -2.30 |
| EPS Diluted | -0.12 | 0.04 | -1.32 | -1.07 | -2.30 |
| Weighted Avg Shares Out | 90.00M | 90.00M | 90.00M | 81.04M | 75.80M |
| Weighted Avg Shares Out (Dil) | 90.00M | 90.00M | 90.00M | 81.04M | 75.80M |
Source: https://incomestatements.info
Category: Stock Reports